

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LANSEN PHARMACEUTICAL HOLDINGS LIMITED

朗生醫藥控股有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 503)

POSITIVE PROFIT ALERT

This announcement is made by Lansen Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries shall be referred to as the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA Insider Information Provisions (as defined in the Listing Rules) of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong) (the “**SFO**”).

The board (the “**Board**”) of directors of the Company wishes to inform the shareholders of the Company and potential investors that based on the preliminary review of the unaudited consolidated management accounts of the Group for the twelve months ended 31 December 2022 (“**FY2022**”), the Group is expected to record a net profit attributable to equity owners of approximately US\$8.1 million, representing an increase of approximately US\$7.2 million (approximately 798% increase) compared to that of last year of approximately US\$0.9 million.

The above expected high growth rate in net profit attributable to equity owners was mainly due to (i) the Group’s sales strategy adjustments aimed to penetrate into lower-tier markets and increase hospitals coverage and the reorganisation of the management structure having shown initial results, resulting in an increase in sales and gross profit; and (ii) the small net profit attributable to equity owners last year formed a low base for comparison with FY2022. In comparing the profit from operations of the Group for FY2022 to that for last year, the expected growth rate is approximately 155%.

The information contained in this announcement is only a preliminary estimate made by the management of the Company based on the unaudited consolidated management accounts of the Group for FY2022 and the information currently available, which have not been reviewed or audited by the auditors of the Company nor approved by the audit committee of the Company. Therefore, the actual results of the Group for the FY2022 may be different from the information contained herein. The Group’s FY2022 results are expected to be announced by the end of March 2023.

Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
Lansen Pharmaceutical Holdings Limited
Wu Zhen Tao
Chairman

Hong Kong, 13 January 2023

As at the date of this announcement, the executive managing Director is Mr. Chen Li; the non-executive Directors are Mr. Wu Zhen Tao and Ms. Liu Xuezi; the independent nonexecutive Directors are Mr. Chan Kee Huen, Michael, Mr. Yeung Tak Bun, Allen, Ms. Chan Ching Har, Eliza and Dr. Zhu Xun.